<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 - 13:40</td>
<td>Welcome Reception</td>
<td>Hall 1</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Opening and Welcome</td>
<td>Room B</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Grunenwald, FR; J. Vansteenkiste, BE</td>
<td></td>
</tr>
<tr>
<td>13:45 - 13:50</td>
<td>Welcome to the Conference</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Grunenwald¹, J. Vansteenkiste², ¹FR, ²BE</td>
<td></td>
</tr>
<tr>
<td>13:50 - 13:55</td>
<td>Introduction by the ESMO President</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Stahel, CH</td>
<td></td>
</tr>
<tr>
<td>13:55 - 14:00</td>
<td>Introduction by the IASLC President</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T. Mok, CN</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>The development of oncological platforms across Europe</td>
<td>Room B</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Grunenwald, FR; J. Vansteenkiste, BE</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>The development of oncological platforms across Europe</td>
<td>Room B</td>
</tr>
<tr>
<td></td>
<td>R. Stahel, CH</td>
<td></td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>Local control after treatment of early stage lung cancer</td>
<td>Room B</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Zips, DE; D. Jones, US</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>Stereotactic ablative RT after surgical treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Senan, NL</td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:10</td>
<td>Surgery after stereotactic ablative RT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P. Van Schil, BE</td>
<td></td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Surgery after radiofrequency ablation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. Dienemann, DE</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>Surgery for metachronous lung tumours</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Jones, US</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Questions and Answers</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>14:30</td>
<td>The evolving role of immunotherapy for lung cancer</td>
<td>Chair: A.-M. Dingemans, NL; M. Reck, DE</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>Checkpoint inhibitors: State of the art</td>
<td>S. Peters, CH</td>
</tr>
<tr>
<td>14:50 - 15:10</td>
<td>Combination strategies</td>
<td>M. Reck, DE</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Is there any room left for vaccines in lung cancer?</td>
<td>J. Vansteenkiste, BE</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>Clinical trial design and perspectives</td>
<td>D. Carbone, OH/US</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Questions and Answers</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Mesothelioma: The rare disease that we need to know better</td>
<td>Chair: P. Baas, NL; W. Weder, CH</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td>Sequencing the mesothelioma genome in 2015</td>
<td>G. Scagliotti, IT</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>The evolving role of the thoracic surgeon</td>
<td>W. Weder, CH</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Radiotherapist: A controversial role in this disease</td>
<td>U. Ricardi, IT</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td>Systemic treatment: Old drugs or new approaches?</td>
<td>P. Baas, NL</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Questions and Answers</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Chair(s)</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>16:30 - 18:00</td>
<td><strong>Toxicity management of targeted agents</strong></td>
<td>E. Smit, NL</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td>Management of skin toxicity</td>
<td>V. Sibaud, FR</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Other toxicities of targeted agents and their management</td>
<td>S. Novello, IT</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Interactions between targeted agents and concomitant meds including life style</td>
<td>R. Mathijssen, NL</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td>Interaction between radiotherapy and targeted agents: Toxicity issues</td>
<td></td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Questions and Answers</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04-16-2015</td>
<td><strong>Oncogene-driven early stage NSCLC</strong></td>
<td>Y.-L. Wu, CN; M. Kris, US</td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Should we test for EGFR and ALK in completely resected NSCLC?</td>
<td>Y.-L. Wu, CN</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>How should completely resected stage II-III with activating EGFR mutation be treated? ongoing studies</td>
<td>M. Kris, NY/US</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04-16-2015</td>
<td><strong>How do we provide the best psychological care for patients with thoracic malignancies?</strong></td>
<td>J.-L. Pujol, FR; T. Berghmans, BE</td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>The holistic approach of the patient</td>
<td>J.-L. Pujol, FR</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>The provision of early palliative care</td>
<td>T. Berghmans, BE</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
### Molecularly-driven targeted agents for advanced NSCLC

**Room X**

**Chair:** R. Califano, UK; M. Petrova, BG

- **08:00 - 08:20**
  - Overcoming resistance to first-/second-generation EGFR-TKIs and ALK-inhibitors in oncogene-addicted advanced NSCLC
    - **R. Califano,** UK

- **08:20 - 08:40**
  - Novel therapies for advanced squamous cell carcinoma
    - **G. Mountzios,** GR

- **08:40 - 08:50**
  - Discussion

---

### Management of neuro-endocrine tumours other than SCLC

**Room A**

**Chair:** R. Cerfolio, US; C. Gridelli, IT

- **09:00 - 09:20**
  - Radionuclide techniques for staging and treatment
    - **E. Baudin,** FR

- **09:20 - 09:40**
  - Local therapies
    - **B. Passlick,** DE

- **09:40 - 10:00**
  - Systemic therapy
    - **C. Gridelli,** IT

- **10:00 - 10:20**
  - Review of a current guideline
    - **P. Ferolla,** IT

- **10:20 - 10:30**
  - Questions and Answers

---

### Is immunotherapy a first-line treatment for NSCLC?

**Room B**

**Chair:** F. Hirsch, US; J. Vansteenkiste, BE

- **09:15 - 10:15**
  - Introduction and first vote

- **09:25 - 09:45**
  - Yes
    - **J.-C. Soria,** FR

- **09:45 - 10:05**
  - No
    - **K. O'Byrne,** AU

- **10:05 - 10:15**
  - Second vote and conclusions

---

### Medical and radiation oncology

**Room V**

**Chair:** C. Manegold, DE; G. Scagliotti, IT; S. Senan, NL
100PD - A prospective randomized open label phase III study of maintenance gemcitabine versus best supportive care following platinum-paclitaxel chemotherapy for patients with advanced non-small cell lung cancer
S. Jakhar, S. Narayan, A. Kapoor, S. Beniwal, M. Singhal, P. Kumari, G. Singh, S. Kumari, H. Kumar, M. Bardia; IN

101PD - A prospective randomized open label phase III study of gefitinib versus docetaxel as second or third line therapy in patients with advanced non small cell lung cancer in Asian Indians
A. Kapoor, N. Kumar, S. Narayan, R. Nirban, S. Maharia, S. Beniwal, S. Jakhar, H. Kumar; IN

Invited Discussant
C. Manegold, DE

Discussion

102PD - A randomized, double-blind, phase 2 trial of veliparib (ABT-888) with carboplatin and paclitaxel in previously untreated metastatic or advanced non-small cell lung cancer
J. Mazieres¹, N. Blais², E. Juhasz³, L. Urban³, S. Orlov⁴, Q. Qin⁵, M. McKee⁵, V. Giranda⁵, V. Gorbunova⁴, S. Ramalingam⁶, ¹FR, ²CA, ³HU, ⁴RU, ⁴IL/US, ⁶GA/US

103PD - Subgroup analysis of elderly patients in SQUIRE: A randomized, multicenter, open-label, phase III study of necitumumab (N) plus gemcitabine-cisplatin (GC) chemotherapy versus GC alone in first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
N. Thatcher¹, T.-E. Ciuleanu², R. Ramlau³, C. Schumann³, L. Paz-Ares¹, H. Depenbrock⁴, S. Nanda⁵, N. Chouaki⁶, M. Sociinski⁷, ¹UK, ²RO, ³PL, ⁴DE, ⁵NJ/US, ⁶FR, ⁷PA/US

37PD - SNPs in angiogenic factors as predictive markers for outcome in patients (p) with advanced non-squamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel (CP) and bevacizumab (Bev). Final results of ANGIOMET Spanish Lung Cancer Group Trial

LBA4 - Evaluation of anaplastic lymphoma kinase (ALK) inhibitor brigatinib [AP26113] in patients (Pts) with ALK+ non–small cell lung cancer (NSCLC) and brain metastases
D. Kerstein¹, S. Gettinger¹, K. Gold², C. Langer¹, A. Shaw¹, L. Bazhenova³, R. Salgia⁴, D. Dorer¹, M. Conlan¹, D..R. Camidge⁵, ¹US, ²TX/US, ³CA/US, ⁴IL/US, ⁵CO/US

Invited Discussant
G. Scagliotti, IT

Discussion
10:00 - 10:00 82PD - The volume matters in stage III NSCLC patients treated with concurrent chemoradiotherapy
J. van Diessen, C. Chen, W. Heemsbergen, M. van den Heuvel, J. Belderbos, J.-J. Sonke; NL

10:00 - 10:00 83PD - Prognosis of stage III non-small-cell lung cancer patients presenting with isolated brain failure after definitive concurrent chemoradiation therapy
E. Topkan, O. Guler, B. Yildirim; TR

10:00 - 10:20 Invited Discussant
S. Senan, NL

10:20 - 10:30 Discussion

11:00 - 12:30 How do we improve the outcome of stage III NSCLC? Room B
Chair: B. Passlick, DE; W. Eberhardt, DE

11:00 - 11:20 Selection of patients for multimodality treatment decision
W. Eberhardt, DE

11:20 - 11:40 Optimal staging of mediastinal lymph nodes
C. Dooms, DE

11:40 - 12:00 The place of neo-adjuvant or adjuvant radiotherapy
C. Le Pechoux, FR

12:00 - 12:20 Improving stage III outcome: Any perspective?
P. De Leyn, BE

12:20 - 12:30 Questions and Answers / Panel Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:30</td>
<td>Personalised radiotherapy</td>
<td>Room A</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>The role of genetics in personalised radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. West, UK</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Organs at risk: How to individualise?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. De Ruysscher, BE</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Radiomics for tumours: The future for personalised radiotherapy?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>O. Gevaert, US</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>How to individualise the combination of radiotherapy with drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Zips, DE</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Contemporary resection techniques for stage I lung cancer</td>
<td>Room C</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Minimally invasive open and hybrid techniques: Morbidity and long term results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. Asamura, JP</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Conventional VATS lobectomy/segmentectomy: Morbidity and long term results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Assouad, FR</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Uniportal VATS lobectomy/segmentectomy: Morbidity and long term results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Gonzales-Rivas, ES</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Robotic lobectomy/segmentectomy: Morbidity and long term results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Cerfolio, AL/US</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
11:00 - 12:30  The diagnostic challenge of small nodules  Room W
Chair: J. Vansteenkiste, BE; G. Veronesi, IT

11:00 - 11:20  Optimal follow-up of incidental nodules  
W. De Wever, BE

11:20 - 11:40  Possibilities and limitations of endoscopy  
V. Ninane, BE

11:40 - 12:00  Possibilities and limitations of transthoracic procedures  
S. Diederich, DE

12:00 - 12:20  Can biomarkers be of help in the diagnosis?  
G. Veronesi, IT

12:20 - 12:30  Questions and Answers / Panel Discussion

11:00 - 12:30  Pathology in translation  Room X
Chair: A. Warth, DE; E. Thunnissen, NL

11:00 - 11:20  Proliferation in lung cancer: Worth measuring?  
A. Warth, DE

11:20 - 11:40  EQA for biomarker testing on the move  
E. Thunnissen, NL

11:40 - 12:00  Diagnosing mesothelioma: An ongoing challenge  
S. Dacic, PA/US

12:00 - 12:20  Liquid biopsies: CTCs and cell-free DNA for monitoring NSCLC  
S. Finn, US

12:20 - 12:30  Questions and Answers / Panel Discussion

12:30 - 13:10  Poster lunch  Hall 1

12:30 - 12:30  TUMOUR BIOLOGY AND PATHOLOGY

12:30 - 12:30  2P - EGFR mutation is not a rare issue for peripheral squamous carcinoma of lung  
Q. Zhang, L. Zhu, P. Gu, Y. Zhang, B. Han, J. Zhang; CN

12:30 - 12:30  3P - EGFR mutations in non-small cell lung cancer in South Africa  
S.W. Chan, C. Maske, P. Ruff; ZA

12:30 - 12:30  5P - Reliable EGFR mutation testing in ultrasound guided supraclavicular lymph node fine needle aspirates: A cohort study with diagnostic performance analysis
12:30 - 12:30

6P - Screening for the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients in the Levant area, a prospective analysis

A. Awwad, S. Tiwari, V. Sovani, D. Baldwin, M. Kumaran; UK

12:30 - 12:30

7P - Frequency of ALK gene rearrangement in Saudi lung cancer

F. Al Davel, H. Al Husaini, S. Mohammed, A. Tulbah, K. Al Kuraya; SA

12:30 - 12:30

8P - PD1/PD-L1 expression in NSCLC differs according to localisation, grading and subtype

F. Brühl, A. Csanadi, C. Kayser, S. Wiesemann, J. Rawluk, M. Werner, G. Kayser; DE

12:30 - 12:30

9P - Distribution of T cells in non-small cell lung cancer tissue according to COPD and smoking status

J. Jackute, M. Zemaitis, D. Pranys, B. Sitkauskiene, S. Miliauskas, R. Sakalauskas; LT

12:30 - 12:30

10P - Allele frequency of ABO and Rh blood group and the risk of non small cell lung carcinoma

A. Kapoor, N. Kumar, A. Kalwar, S. Narayan, R. Nirban, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar, A. Sharma; IN

12:30 - 12:30

11P - The comparative estimation of estrogen receptor beta expression in primary and metastatic lung cancer

T. Bogush, E. Dudko, A. Bogush, G. Grishanina, V. Kirsanov, R. Ramanauskaite, B. Polotsky, S. Tjulandin, M. Davydov; RU

12:30 - 12:30

12P - A molecular case–control investigation of the merkel cell polyomavirus prevalence in Vietnamese non-small-cell lung-cancer

T. Ngo, VN

12:30 - 12:30

13P - Expression of IRAK-1 and EZH-2 in imprints of NSCLC and preneoplastic lesions

K. Hainis, A.-M. Athanassiadou, E. Haini, A. Tsiapis, M. Gonidi, P. Athanassiadou; GR

12:30 - 12:30

14P - “Different trend” in multiple primary lung cancer and intrapulmonary metastasis

C. Shen, G. Che; CN

12:30 - 12:30

15P - Clinicopathological analysis of primary pulmonary lymphoepithelioma-like carcinoma

C. Shen, G. Che; CN

12:30 - 12:30

16P - Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing

Y. Shi, D. Tao, S. Yang, X. Han, D. Wu, N. Zhang; CN

12:30 - 12:30

17P - Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) of the lung using next-generation sequencing (NGS)

N. Chilingirova, L. Balabanski, D. Toncheva, G. Kurteva, D. Damyanov, P. Chilingirov; BG

12:30 - 12:30

18P - Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as serum marker of bone metastases from non-small cell lung cancer (NSCLC) and breast cancer. Preliminary results

F. Lumachi, A. Del Conte, F. Mazza, S. Basso, G. Chiara; IT

12:30 - 12:30

19P - Fine needle aspiration cytology of thymic epithelial neoplasms: A cytologic-histologic correlation analysis from a referral institution


25P - A common BIM deletion polymorphism was associated with the risk of lung cancer in a Chinese population
X. Jing, CN

27P - Characteristics of lung cancer diagnosed with low dose chest CT screening
S. Choi, C. Lee; KR

28P - Sex differences in presentation, management and prognosis of Moroccan patients with non small cell lung carcinoma: A retrospective analysis of 224 cases
L. Amaadour, L. Boudahna, Z. Benbrahim, S. Arifi, N. Mellas; MA

29P - The risk of lung cancer among women who start smoking as teenagers
M. Tagbarha, NG

30P - The beliefs, orientation, knowledge, understanding, attitudes and treatment access to lung cancer amongst rural men in Nigeria
M. Tagbarha, NG

31P - Plasma CRABP2 in patients with non-small cell lung cancer
S.-S. Han, H.-Y. Lee, S.-J. Lee, W.J. Kim, Y. Hong, E.J. Lee; KR

32P - Epidemiology, treatment patterns and survival outcome in patients of advanced stage inoperable lung cancer: A tertiary cancer care centre analysis
D. Kumar, M. Pant, S. Singh; IN

33P - Idiopathic pulmonary fibrosis as a poor prognostic factor in lung cancer patients
C. Son, S. Um, M.-S. Roh; KR

41P - The comparative estimation of TUBB3 expression in non-small-cell lung carcinoma and adjacent lung tissue
T. Bogush, L. Mamichev, E. Dudko, A. Grishanina, R. Ramanauskaitė, N. Vichljantzeva, S. Tjulandin, B. Polotsky, M. Davydov; RU

42P - Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells
M. Filipiska, M. Skrzypski, G. Stasioj, J. Bigda; PL

43P - miR31-3p expression in patients with advanced lepidic adenocarcinoma (L-ADC) treated with EGFR TKI in IFCT 0401 and 0504 trials

44P - Upregulated miRNA 21 in KRAS mutated patients is related to prognosis in resectable non-small cell lung cancer
S. Gallach, S. Calabuig-Fariñas, E. Jantus-Lewintre, D. Montaner, E. Escorihuela, A. Blasco, R. Guijarro, C. Camps; ES
12:30 - 12:30 45P - MicroRNA expression profiling in lung cancer and normal tissue using massively parallel sequencing technique

12:30 - 12:30 46P - Antitumor efficacy of the double suicide genes in lung cancer cells
C. Shen, G. Che; CN

12:30 - 12:30 47P - Pharmacogenetics & treatment outcome in cancer patients receiving radio-chemotherapy
S. Yadav, V. Chauhan, D. Parmar; IN

12:30 - 12:30 48P - Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derived xenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
E. Stewart\textsuperscript{1}, S. Sakashita\textsuperscript{1}, T. Wang\textsuperscript{1}, N.-A. Pham\textsuperscript{1}, M. Li\textsuperscript{1}, G. Liu\textsuperscript{1}, M. Tsao\textsuperscript{2,\textsuperscript{3}}, ON/CA, CA

12:30 - 12:30 49P - Synergistic effect of histone deacetylase inhibitor in combination with epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-TKI resistant non-small cell lung cancer cell lines
X. Han, N. Zhang, J. Yao, Y. Shi; CN

12:30 - 12:30 50P - Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector, an effective in vivo device for capturing CTCs

12:30 - 12:30 51P - Gef gene: A new suicide gene therapy for non-small cell lung cancer

12:30 - 12:30 52P - Multiparameter ploidy profiling: A powerful tool to investigate the genomics of diploid tumor populations
T. Lorber\textsuperscript{1}, S. Rau\textsuperscript{1}, V. Perrina\textsuperscript{1}, M. Barrett\textsuperscript{2}, C. Ruiz\textsuperscript{1}, L. Bubendorf\textsuperscript{1}; \textsuperscript{1}CH, \textsuperscript{2}AZ/US

12:30 - 12:30 IMAGING AND STAGING

12:30 - 12:30 55P - Proposed new simple criteria of clinical multiple primary lung cancers
T. Matsunaga, K. Suzuki, K. Takamochi, S. Oh; JP

12:30 - 12:30 56P - FDG PET/CT for evaluation of mediastinal lymph node staging using FDG uptake and volumetric CT histogram in non-small cell lung cancer

12:30 - 12:30 SCLC

12:30 - 12:30 57P - Inhibition of the focal adhesion kinase has anti-tumoral effect in small-cell lung cancer cell lines
F. Aboubakar\textsuperscript{1}, M. Lecocq\textsuperscript{1}, B. Detry\textsuperscript{1}, L. Maha\textsuperscript{1}, P.P. Massion\textsuperscript{2}, Y. Sibille\textsuperscript{1}, C. Pilette\textsuperscript{1}, S. Ocak\textsuperscript{1}; \textsuperscript{1}BE, \textsuperscript{2}TN/US

12:30 - 12:30 58P - Radiation therapy (RT) in the palliative treatment of metastatic small cell lung cancer (SCLC)
Y. Raquin, I. Ivanova, I. Gulidov, Y. Mardynsky, A. Zolotkov, D. Gogolin, L. Kursova; RU
12:30 - 12:30  EARLY STAGE NSCLC

12:30 - 12:30  66P - Prognostic classification of lung adenocarcinoma by integrated miRNA-mRNA expression profiles
S. Tam¹, M. Pintilie¹, N. Liu¹, J. McPherson², M. Tsao², ¹ON/CA, ²CA

12:30 - 12:30  67P - mRNA expression level of lymphangiogenesis-associated genes in early-stage non-small cell lung cancer
O. Kowalczyk, M. Koziolowski, W. Laudanski, J. Kislik, J. Niklinski; PL

12:30 - 12:30  68P - The utility of actinin-4 protein overexpression as a predictive biomarker for therapeutic effect of adjuvant chemotherapy to the resected lung adenocarcinoma
H. Shiraishi¹, Y. Fujiwara¹, T. Kakuya¹, K. Tsuta¹, S. Watanabe¹, W. Huang², T. Yamada¹, H. Asamura¹, Y. Ohe¹, K. Honda¹, ¹JP, ²TW

12:30 - 12:30  69P - The impact of genetic alteration on recurrence in patients with resected stage I non-small cell lung cancer
H.S. Chung, E.Y. Heo, S.S. Park, Y.S. Park, Y.W. Kim, D.K. Kim; KR

12:30 - 12:30  70P - Prognostic role of T-regulatory cells in completely resected early stage non-small cell lung carcinoma
F. Kose¹, H. Abali¹, A. Fndkcoglu¹, T. Canpolat¹, A. Besen¹, A. Sumbul¹, H. Mertsoylu², A. Sedef¹, O. Ozyilkan¹, ¹TR, ²TN

12:30 - 12:30  71P - Outcome after SBRT for potentially operable NSCLC patients

12:30 - 12:30  72P - Occurrence of significant tumor volume changes during stereotactic body radiation therapy for lung cancer
F. Charlier, L. Moretti, Y. Jourani, T. de Brouwer, P. Van Houtte; BE

12:30 - 12:30  73P - Outcome of early-stage lung cancer treated with stereotactic body radiotherapy (SBRT)
M. Alameddine, J. Chan, A. Pope, A. Haridass, A. Baker, S. Meara, R. Clements, A. Crabtree, H. Wong, C. Eswar; UK

12:30 - 12:30  74P - Does a higher surgical resection rate in lung cancer lead to a higher rate of post-operative multi-station N2 disease?

12:30 - 12:30  75P - Adequacy of lymph node sampling during surgical resection of lung cancer at a regional UK thoracic surgical centre 2011-2013

12:30 - 12:30  76P - Result of the 6-minute walk test is an independent prognostic factor of surgically treated non-small cell lung cancer
T. Marianski, M. Badocha, D. Wnuk, A. Mosiewicz, W. Rzyman; PL

12:30 - 12:30  77P - Post-operative outcomes in non-small cell lung cancer patients with mild to moderate stage chronic obstructive pulmonary disease

Last update: 09-03-2015 04:51:41pm
12:30 - 12:30  78P - Examination of prognostic factors in cases receiving UFT as postoperative adjuvant chemotherapy for lung cancer
K. Nawa, R. Yoneyama, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda; JP

12:30 - 12:30  79P - Volume changes with hypo-fractionated radiotherapy in early lung cancer: Time trends & outcomes
R. Pathak, A. Tibdewal, S. Ghosh Laskar, S. Chaudhari, J.P. Agarwal; IN

12:30 - 12:30  80P - Role of treatment in international differences in one-year mortality from early stage non-small cell lung cancer: A tentative answer from the International Cancer Benchmarking Partnership study
T. Solomon, M. Peake, J. Butler, M. Coleman, W. Evans, E. Jakobsen, M. Boyer, T. Johannesen, B. Rachet; UK, ON/CA, DK, NSW/AU, NO

12:30 - 12:30  LOCALLY ADVANCED NSCLC

12:30 - 12:30  84P - Trimodality therapy including radical resection for pancoast tumors: T4 is not a contraindication for radical surgery
M. Hoda, R. Waseda, T. Klikovits, O. Foesleitner, S. Zoechbauer-Mueller, K. Dieckmann, H. Prosch, R. Pirker, W. Klepetko; AT

12:30 - 12:30  85P - Review of radical radiotherapy +/- chemotherapy for stage III NSCLC
M. Button, R. Evans, E. Rees, C. Bullock; UK

12:30 - 12:30  86P - Can concurrent chemo-radiation be delayed by induction chemotherapy in the curative treatment of stage III non-small cell lung carcinoma?: A pooled analysis
C. Guilbault, A. Garani, M. Almajed, S. Faria, S. Owen, M. Duclos, L. Ofiara, J. Gruber, V. Hirsh, N. Kopek; QC/CA, CA

12:30 - 12:30  87P - What to do for the treatment of non small cell lung cancer (NSCLC) with a single mediastinal lymph node involvement (N2a disease) in developing countries?
F. Caushi, H. Hafizi, A. Mezini, D. Xhemalaj, I. Skenduli; AL

12:30 - 12:30  88P - Omission of elective nodal irradiation has no impact on isolated elective nodal failure and survival outcomes in stage III non-small-cell lung cancer patients treated with definitive concurrent chemoradiotherapy
E. Topkan, O. Guler, B. Yildirim; TR

12:30 - 12:30  89P - Clinical factors of nodal upstaging in pathologic N1 or N2 non-small cell lung cancer
Y. Moon, S.W. Sung, K.S. Kim, J.K. Park; KR

12:30 - 12:30  90P - Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin in inoperable stage III non-small cell lung cancer
H. Mertsoglu, F. Kose, A. Sedef, O. Dogan, C. Parlak, A. Besen, A. Sumbul, A. Sezer, A. Fndkcgol, S. Muallaoglu; 1TN, 2TR

12:30 - 12:30  91P - Definitive concomitant radiochemotherapy (RCT) treatment for locally advanced (LA) non small cell lung cancer (NSCLC): Evaluation of hematological and esophageal toxicity in the Radiation Oncology Department of University of Florence experience

Last update: 09-03-2015 04:51:41pm  ELCC 2015
12:30 - 12:30 92P - Social deprivation and radical treatment of stage III NSCLC  
M. Button, R. Evans, C. Bullock, E. Rees; UK

12:30 - 12:30 93P - The clinical characteristics of 50 patients with radiation-induced pneumonia  
R. Liu, Q. Zhang, X. Wang; CN

12:30 - 12:30 94P - Lung cancer in women, a different disease: Survival differences by sex  
A. Ulas, S.T. Tokluoglu, M. Kös, K. Silay, S. Akinci, B. Oksuzoglu, N. Alkis; TR

12:30 - 12:30 ADVANCED NSCLC

12:30 - 12:30 111P - Ceritinib treatment of patients (Pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases: ASCEND-1 trial experience  
D.-W. Kim¹, R. Mehra², D. Tan³, E. Felip⁴, T. Szczudlo⁵, S. Sutradingar⁵, K. Rodríguez Lorenc⁵, A. Shaw⁶, ¹KR, ²PA/US, ³SG, ⁴ES, ⁵NJ/US, ⁶US

12:30 - 12:30 112P - Efficacy and safety of imprime PGG, a novel innate immune modulator, in combination with bevacizumab (Bev), carboplatin and paclitaxel for the 1st-line treatment of stage IV NSCLC  
A. Braun¹, W. Engel-Riedel², F. Schneller², M. Wolf², W. Schuette², J. Lowe¹, P. Mattson¹, M. Gargano¹, M. Patchen¹, R. Huhn¹; ¹US, ²DE

12:30 - 12:30 113P - Anlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer: A multicentre, randomized, double-blind, placebo-controlled, phase II trial (NCT01924195)  
B. Han, K. Li, Y. Zhao, B. Li, Y. Cheng, J. Zhou, Y. Lu, Y. Shi, Z. Wang, L. Jiang; CN

12:30 - 12:30 114P - A phase 1b study of anti-DLL4 (delta-like ligand 4) antibody demcizumab (DEM) with pemetrexed (PEM) and carboplatin (CARBO) in patients with 1st-line non-squamous NSCLC  
J. Dupont¹, M. McKeage², D. Kotasek³, B. Markman³, M. Hidalgo⁴, M. Millward⁵, M. Jameson², D. Harris², R. Stagg⁶, B. Hughes⁷; ¹CA/US, ²NZ, ³AU, ⁴ES, ⁵WA/AU, ⁶US, ⁷QLD/AU

12:30 - 12:30 115P - KIF5B & CCDC6 RET in lung cancer: Clinical insights and response to personalized based therapy  

12:30 - 12:30 116P - Clinical characteristics and response to EGFR TKI in never smoker squamous lung cancer  
S. Ee, S. Young, E.H. Tan, D. Lim, G.S. Tan, A. Jain, W. Zeng, T. Lim, A. Takano, D. Tan; SG

12:30 - 12:30 117P - German country-wide surveys from 2012 and 2014 about EGFR mutational testing algorithms adopted by medical doctors in patients with NSCLC  
H. Ostermann, D. Ukena, S. Radke, A. Freitag, S. Hörmig; DE

12:30 - 12:30 118P - Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer: Phase IIIB study  

12:30 - 12:30 119P - Reversible versus irreversible EGFR tyrosine-kinase inhibitors for non-small-cell lung cancer (NSCLC): A preclinical and pharmacokinetic comparison
12:30 - 12:30 120P - Is switch maintenance therapy mandatory for EGFR mutated patients initiated on chemotherapy? 
R. Roy; IN

12:30 - 12:30 121P - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations 
Y. Zhang, B. Han, B. Jin, Y. Lou, R. Li, X. Zhang, S. Hu; CN

12:30 - 12:30 122P - Icotinib as first-line treatment for elderly patients with EGFR 19 or 21 mutation in advanced NSCLC: A phase-IV, open-label, single-arm study 
B. Han, C. Shi, J. Qian, R. Li; CN

12:30 - 12:30 123P - Outcomes of octogenarian (80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience from The Christie Hospital 
M. Howell, J. Chiramel, N. Flaum, A. Lewis, Y. Summers, P. Taylor, A. Chittalba, H. Sheikh, F. Blackhall, R. Califano; UK

12:30 - 12:30 124P - Platinum based chemotherapy for the treatment of elderly patients with metastatic non small cell lung carcinoma: A retrospective analysis of a single institution 
L. Amaadour, L. Boudahna, Z. Benbrahim, S. Arifi, N. Mellas; MA

12:30 - 12:30 125P - A prospective randomized phase III study of palliative chemotherapy versus best supportive care in elderly patients with advanced non-small cell lung cancer: Survival analysis and ECOG performance status regression analysis 

12:30 - 12:30 126P - Outcomes over a decade in stage IV non-small cell lung cancer (NSCLC): The Clatterbridge Cancer Centre experience 
C. Escriu, H. Wong, E. Marshall; UK

12:30 - 12:30 127P - A prospective randomized phase III study evaluating quality of life in advanced non-small cell lung cancer receiving platinum based chemotherapy combination in old versus new standard chemotherapy regimen 
A. Rungta, A. Kapoor, S. Dutta; IN

12:30 - 12:30 128P - Comparison of efficacy of pemetrexed plus platinum and non-pemetrexed plus platinum as 1st line chemotherapy in EGFR wild type non-squamous NSCLC 

12:30 - 12:30 129P - Effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous non-small cell lung cancer 

12:30 - 12:30 130P - Maintenance pemetrexed in NSCLC - outcome analysis from a tertiary care center 
A. Pandey, K. Prabhash, V. Noronha, A. Joshi; IN

12:30 - 12:30 131P - Duration and tolerance of maintenance pemetrexed (mPem) treatment for advanced non-small cell lung cancer 
P. Charlton, E. Josephides, E. Karapanagiotou, A. Montes, J. Spicer, R. Lal; UK
12:30 - 12:30  132P - Weekly carboplatin and paclitaxel in advanced non-small cell lung cancer: Good response rate but poor overall survival in a "real world" population
M. Mark1, V. Volk2, U. Mey1, P. Brossart2, R. Von Moos1, R. Cathomas1; 1CH, 2DE

12:30 - 12:30  133P - An estimation of the population-based survival benefit of first-line chemotherapy for lung cancer
V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton; AU

12:30 - 12:30  134P - Effect of haematological adverse effects occurring during chemotherapy on response to treatment and progression free survival in advanced NSCLC
A. Nagy, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel; EG

12:30 - 12:30  135P - Significance of thyroid transcription factor 1 expression in patients with nonsquamous NSCLC treated with pemetrexed based chemotherapy

12:30 - 12:30  136P - TTF1 expression in advanced non-small cell lung cancer: Impact on survival outcome
S. Elsamany1, T. Al-faye2, W. Abozeed1, A. Alzahran1, M. Farooq2, W. Darwish1, A. Almadani2, E. Bukhan2; 1EG, 2SA

12:30 - 12:30  137P - Risk factors for skeletal-related events in patients with non-small cell lung cancer patients with bone metastases
A. Ulas, A. Bilici, S.T. Tokluoglu, S. Akin, K. Silay, F. Paksoy Turkoz, A. Durnali, B. Oksuzoglu, N. Alkis; TR

12:30 - 12:30  METASTASES TO AND FROM THE LUNG

12:30 - 12:30  146P - Stereotactic ablative radiotherapy (SART) of lung lesion in oligometastatic patients: The importance of high doses delivery

12:30 - 12:30  147P - Different metastatic pattern according to the EGFR mutational status in a cohort of lung adenocarcinomas (ADCs): A single-institution report
A. Russo, T. Franchina, A. Picone, G. Ferraro, M. Picciotto, M. Zanghi, V. Franchina, V. Adamo; IT

12:30 - 12:30  148P - Incidence of brain metastases identified upon initial diagnosis in different histological types of lung cancer: A single department experience
G. Drpa, F. Popovic, I. Markelic, S. Kukulj; HR

12:30 - 12:30  149P - Presentation and patterns of care of lung cancer patients with brain metastasis at a tertiary care centre In India
A. Tibdewal, R. Pathak, S. Ghosh Laskar, K. Prabhash, G. Karimundackal, J.P. Agarwal; IN

12:30 - 12:30  150P - Usefulness of lung palpation through thoracotomy for metastasectomy in patients with non-imaged pulmonary nodules
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30  151P - Post-treatment effects of lung cancer on spinal fracture
M. Tagbarha, NG
12:30 - 12:30  152P - Transarterial chemoembolisation using drug-eluting microspheres DEM-TACE in lung carcinoma metastases to the liver in humans
B. Rybacka-Chabros, K. Pyra, T. Jargieo, M. Szczepro Trojowska, P. Chabros, J. Milanowski; PL

12:30 - 12:30  153P - Factors affecting survival in patients with pulmonary metastases from colorectal cancer with previously resected liver metastases who underwent lung metastasectomy
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30  154P - Surgical treatment of synchronous lung metastasis in patient with osteosarcomas and soft tissue sarcomas
E. Smolenov, Y. Ragulin, A. Starodubtcev, A. Kurilchik, V. Usachev, A. Zubarev, V. Ivanov; RU

12:30 - 12:30  MESOTHELIOMA

12:30 - 12:30  157P - Pleural malignant mesotheliomas over-express PD-L1
A. Voss, J. Xiu, S. Millis, Z. Gatalica; CH, AZ/US, US

12:30 - 12:30  158P - New therapeutic approach for mesothelioma
Y. Sakata, M. Takahashi, Y. Ino, T. Todo, N. Ikeda; JP

12:30 - 12:30  159P - Impact of maintenance pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: A single institution experience
T. Franchina, A. Russo, A. Picone, G. Ricciardi, F. Raiti, A. Scimone, G. Chiofalo, G. Toscano, V. Adamo; IT

12:30 - 12:30  160P - Pretreatment serum albumin level is an independent prognostic biomarker in malignant pleural mesothelioma
T. Klikovits, P. Stockhammer, Y. Dong, M. Jakopovic, L. Brcic, B. Dome, B. Hegedus, M. Samarzija, W. Klepetko, M. Hoda; AT, HR

12:30 - 12:30  161P - Long-term survival in adults suffered from malignant mesothelioma and pulmonary tuberculosis combined - observational study
B. Rybacka-Chabros, A. Oszywa-Chabros, J. Milanowski; PL

12:30 - 12:30  162P - Statin use and survival in malignant pleural mesothelioma (MPM)
S. Cedres, A. Navarro, A. Martinez, P. Martinez, C. Ortiz, L. Farínñas, E. Felip; ES

12:30 - 12:30  163P - Solitary fibrous tumors of the pleura: Surgical treatment, analysis of our cases from September 1999 to August 2014
F. Gradica, L. Lisha, D. Argjiri, F. Kokici, A. Cami, G. Cerga, P. Hyska, P. Kapisyzi; AL

12:30 - 12:30  MISCELLANEOUS

12:30 - 12:30  164P - Quality in lung cancer care: The Victorian Lung Cancer Registry pilot initial report

12:30 - 12:30  165P - Preoperative positron emission tomography fractal biopsy of thymic epithelial neoplasm
L. Bertolacini, G. Felloni, M. Salgarello, A. Viti, A. Bianchi, A. Terzi; IT

12:30 - 12:30  166P - Accuracy of pleural carcinoembryonic antigen (CEA) assay in patients with benign and malignant pleural effusions requiring thoracentesis

12:30 - 12:30 167P - Improved quality of life of patients with malignant pleural effusion who underwent video-assisted minimally invasive thoracentesis and talc pleurodesis
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30 168P - Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success
S. Alsayed; EG

12:30 - 12:30 169P - Incidence of pain among lung cancer patients hospitalized in Palliative Care Department of Comprehensive Cancer Center – Vratsa for the period 2009 – 2013
N. Yordanov, S. Aleksandrova, D. Yordanova; BG

12:30 - 12:30 170P - Anterior mediastinal mass case series
P. Ramanathan, P. Shivanna, S. Kumar, D. Pandey, S.V.S. Deo, N.K. Shukla; IN

F. Gradica, L. Lisha, D. Argjiri, F. Kokici, A. Cami, G. Cerga, P. Hyska, P. Kapisyzi; AL

12:30 - 12:30 172P - Post-surgical follow-up for non-small cell lung carcinoma (NSCLC): Challenging current practice
F. Iqbal, M. Haris, I. Hussain, S. Ghosh; UK

12:30 - 12:30 173P - Misdiagnosis of lung tuberculosis leads to delaying in lung cancer diagnosis and treatment: Time to use anti-tuberculosis treatment judiciously
R. Devgan, IN

12:30 - 12:30 174P - Mesenchymal tumors of the mediastinum and the role of surgery in their treatment
F. Caushi, H. Hafizi, A. Mezini, I. Skenduli, D. Xhemalaj; AL

12:30 - 12:30 175P - A novel technique for the management of recurent malignant pericardial effusions
N. Panagiotopoulos, D. Patrini, B. Adams, D. Lawrence; UK

12:30 - 12:30 176P - Feasibility of endoscopic transumbilical anatomic lobectomy in a canine model
Y.-H. Liu, TW

12:30 - 12:30 TRIALS IN PROGRESS

12:30 - 12:30 95TiP - A phase 3, randomised, double-blind, placebo-controlled, International study of MEDI4736 in patients with locally advanced, unresectable, stage 3 NSCLC who have not progressed following platinum-based, concurrent chemoradiation therapy (PACIFIC)
B. Creelan¹, N. Iannotti¹, M. Salamat², D. Jayawardene³, M. Ballas³, P. Stockman⁴, S. Antonia¹; ¹FL/US, ²KS/US, ³MD/US, ⁴UK

12:30 - 12:30 138TiP - Ceritinib in patients (pts) with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) metastatic to the brain and/or leptomeninges: The phase II ASCEND-7 study
L. Chow¹, F. Barlesi², E. Bertino³, D.-W. Kim⁴, M. van den Bent⁵, H. Wakelee⁶, P. Wen⁷, P. Cazorla Arratia⁸, J. Shen⁹, F. Branle⁹, ¹US, ²FR, ³OH/US, ⁴KR, ⁵NL, ⁶CA/US, ⁷MA/US, ⁸NJ/US, ⁹CH
12:30 - 12:30 139TiP - Phase 2, open-label, international, non-comparative study of MEDI4736 in patients with locally advanced or metastatic, PD-L1+, stage 3B–4 NSCLC who have received 2 prior systemic treatment regimens (ATLANTIC)

J. Gray1, M. Garassino2, J. Vansteenkiste3, M. Ballas4, D. Jayawardene4, P. Stockman5, J. Powderly6, N. Rizvi7; 1FL/US, 2IT, 3BE, 4MD/US, 5UK, 6NC/US, 7NY/US

12:30 - 12:30 140TiP - AURA3 design: a randomised, Phase III study of AZD9291 versus second-line chemotherapy for patients (pts) with EGFR-TKI-resistant (T790M) advanced non-small cell lung cancer

Y.-L. Wu1, V. Papadimitrakopoulou2, S. Ghiorghiu3, A. Templeton3, T. Mok1; 1CN, 2TX/US, 3UK

12:30 - 12:30 141TiP - AZD9291, a third generation EGFR inhibitor, versus gefitinib or erlotinib in treatment-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring an EGFR-TKI-sensitising mutation (EGFRm): A randomised, phase III study (FLAURA)

S. Ramalingam1, Y. Rukazenkov2, K. Thomas2, J.-C. Soria3; 1GA/US, 2UK, 3FR

12:30 - 12:30 142TiP - Randomized, double-blind, placebo-controlled trial of evofosfamide (TH-302) in combination with pemetrexed in advanced non-squamous non-small cell lung cancer

J. Goldman1, C. Belani2, S. Novello3, J. von Pawel4, T. Czosni5, S. Orlow6, S. Kroll1, T. Pearce2; 1CA/US, 2US, 3IT, 4DE, 5HU, 6RU

12:30 - 12:30 143TiP - SPECTAlung: Screening patients with thoracic tumors for efficient clinical trial access

B. Besse1, J. Menis2, J. Adam1, R. Dziadziuszko3, B. Hasan2, L. Lacroix1, S. Peters4, D. Lacombe2, M. O’Brien5, R. Staehle4; 1FR, 2BE, 3PL, 4CH, 5UK

12:30 - 12:30 144TiP - Open-label single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R) who have failed first-line treatment with platinum-based chemotherapy

S. Thongprasert1, H. Jones2, A. Cseh3, R. Gaafar4; 1TH, 2UK, 3AT, 4EG

14:30 - 16:00 Approaches to TKI resistance

Room A

Chair: B. Besse, FR; T. Mok, CN

14:30 - 14:50 Novel definition of TKI resistance: Clinical versus molecular

G. Oxnard, MA/US

14:50 - 15:10 How to target T790M mutation?

T. Mok, CN

15:10 - 15:30 Management of EGFR-TKI resistance by local therapy, chemotherapy and antiangiogenesis

M. Reck, DE

15:30 - 15:50 Treatment options for ALK-TKI resistance

D.-W. Kim, KR

15:50 - 16:00 Questions and Answers
14:30 - 16:00  New treatment avenues  Room B
Chair: D. De Ruysscher, BE; S. Peters, CH

14:30 - 14:45  60O - Analysis of local recurrences following stereotactic ablative radiotherapy (SABR): Data from a large institutional database
F. Lagerwaard, B. Slotman, M. Dahele, S. Senan; NL

14:45 - 15:00  61O - Outcome of surgical salvage for local failures following stereotactic ablative radiotherapy (SABR)
F. Lagerwaard, M.A. Paul, E. Smit, M.I.M. Versteegh, J.J.A. Joosten, B. Slotman, S. Senan; NL

15:00 - 15:15  Invited Discussant
E. Vallières, US

15:15 - 15:30  81O - Erlotinib as neoadjuvant treatment in endobronchial ultrasound confirmed stage IIIA-N2 non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 or 21) (NCT01217619, ESTERN)A prospective, single arm, phase II clinical trial
L. Xiong, J. Sun, R. Li, Y. Lou, Y. Zhang, A. Gu, L. Jiang, J. Shi; CN

15:30 - 15:45  96O - Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADC histology: IGNITE study
B. Han, L. Xiong, J. Sun, R. Li, Y. Lou, Y. Zhang, A. Gu, L. Jiang, J. Shi; CN

15:45 - 16:00  Invited Discussant
W. Eberhardt, DE

16:30 - 18:00  Locoregional treatment for oligometastatic lung cancer  Room B
Chair: U. Ricardi, IT; P. Van Schil, BE

16:30 - 16:50  Management of oligometastatic lung cancer and brain metastasis
F. Wenz, DE

16:50 - 17:10  Surgery for oligometastatic lung cancer and liver or adrenal metastases
P. Van Schil, BE

17:10 - 17:30  Stereotactic ablative RT for oligometastatic lung cancer
S. Senan, NL

17:30 - 17:50  Surgery for synchronous lung tumours
G. Veronesi, IT

17:50 - 18:00  Questions and Answers

16:30 - 17:45  Advanced NSCLC  Room V
Chair: E. Felip, ES; S. Novello, IT; J. Vansteenkiste, BE
16:30 - 16:30  
**104PD - Phase 2 study of nivolumab (anti-programmed death-1 [PD-1]) in patients (pts) with advanced, refractory squamous (SQ) non-small cell lung cancer (NSCLC)**  
G. Zalcman¹, N. Rizvi², H. Lena¹, J. Wolf³, J. Mazières¹, S. Antonia⁴, E. Minenza⁵, D. Planchard¹, B. Lestini⁶, S. Ramalingam⁷; ¹FR, ²NY/US, ³DE, ⁴FL/US, ⁵IT, ⁶NJ/US, ⁷GA/US

16:30 - 16:30  
**105PD - TG4010 immunotherapy combined with first-line chemotherapy in advanced non-small cell lung cancer (NSCLC). Phase 2b results of the TIME study**  
E. Quoix¹, J. Nemunaitis², Z. Papai³, H. Lena¹, D. Genet¹, C. Louis⁴, M. Cobo⁵, Y. Al Farhat³, B. Marie-Bastien¹, J.M. Limacher; ¹FR, ²TX/US, ³HU, ⁴BE, ⁵ES

16:30 - 16:45  
Invited Discussant  
J. Vansteenkiste, BE

16:45 - 16:55  
Discussion

16:55 - 16:55  
**106PD - EGFR mutation detection in plasma of lung tumor patients in the absence of contributive tissue is a relevant alternative for prescription of tyrosine kinase inhibitors in a routine clinical setting**  
M. Denis, A. Vallée, P. Masson, T. Pigeanne, H. Lacroix; FR

16:55 - 16:55  
**1PD - An integrative analysis of the putative gefitinib-resistant genes in a lung cancer cell line model system**  
X. Han, M. Liu, S. Wang, X. Qian, G. Lv, L. Ma, C. Zeng, Y. Shi; CN

16:55 - 17:10  
Invited Discussant  
E. Felip, ES

17:10 - 17:20  
Discussion

17:20 - 17:20  
**107PD - Afatinib (A) plus paclitaxel (P) following progression on A monotherapy in patients (pts) with metastatic non–small-cell lung cancer (NSCLC) who previously benefited from erlotinib (E)/gefitinib (G): A global randomised phase III trial – LUX-Lung 5 (LL5)**  
M. Schuler¹, J. Yang², K. Park³, V. Chand⁴, B. Wang⁵, D. Planchard⁶, T. Darweesh⁷, ¹DE, ²TW, ³KR, ⁴US, ⁵FR, ⁶EG

17:20 - 17:20  
**108PD - Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 6 (LL6), a phase III global trial**  
G. Goss¹, E. Felip², M. Cobò², S. Lu³, V. Georgoulis⁴, A. Ardizzoni⁵, S. Gadgeel⁶, B. Wang⁵, V. Chand⁶, J.-C. Soria⁷, ¹ON/CA, ²ES, ³CN, ⁴GR, ⁵IT, ⁶US, ⁷FR

17:20 - 17:20  
**109PD - Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harbouring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)**  
M. Schuler¹, J. Yang², L. Sequist³, N. Yamamoto⁴, C. Zhou⁵, C.-P. Hu⁶, K. O'Byrne⁶, V. Hirsh⁷, T. Mok⁵, Y.-L. Wu⁵, ¹DE, ²TW, ³MA/US, ⁴JP, ⁵CN, ⁶QLD/AU, ⁷QC/CA

17:20 - 17:35  
Invited Discussant  
S. Novello, IT
### Medical and surgical oncology

**Room A**

**16:30 - 16:45**

**155O - Chemotherapy of malignant pleural mesothelioma does not preclude use of check-point blockade**

A. Curioni Fontecedro, V. Cecconi, E. Felley Bosco, I. Schmitt-Opitz, W. Weder, R. Stahel, M. van den Broek, V. Tischler; CH

**16:45 - 17:00**

**390 - Immune checkpoints score and CD8+ T cells infiltration are independent prognostic biomarkers in resected NSCLC**

M. Usó, E. Jantus-Lewintre, R. Sirera, S. Calabuig-Fariñas, A. Blasco, R. Guijarro, J. Forteza, C. Camps; ES

**17:00 - 17:15**

**Invited Discussant**

M. Reck, DE

**17:15 - 17:30**

**620 - Thirty and 90-day mortality after lung cancer resection in 2242 patients**

A. Frick, H. Lüders, G. Leschber; DE

**17:30 - 17:45**

**530 - Is routine sampling of the inferior mediastinal lymph node stations a necessity for pre-operative mediastinal staging in lung cancer? Results of a large retrospective study of 986 surgical resections**


**17:45 - 18:00**

**Invited Discussant**

---

### Second ESO Lung Cancer Observatory

**Room X**

**Chair:** M. Aapro, CH; J. Vansteenkiste, BE

**16:30 - 16:45**

**Screening/surgery advances**

D. Grunenwald, FR

**16:45 - 17:00**

**Radiotherapy in extensive disease SCLC (PCI, thoracic RT)**

R. Dziadziuszko, PL

**17:00 - 17:15**

**Anti-PD1 and anti-PDL1 strategies in NSCLC, its potential role in NSCLC treatment**

S. Peters, CH

**17:15 - 17:30**

**Predictive markers in NSCLC (beyond EGFR / ALK)**

K. Kerr, UK

**17:30 - 17:45**

**Long-term lung cancer survivors, patient’s needs (patient representative)**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:50</td>
<td>Heterogeneity in lung cancer: The elephant in the room?</td>
<td>Room A</td>
</tr>
<tr>
<td></td>
<td>Chair: Y. Yatabe, JP; L. Bubendorf, CH</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Impact of tumour heterogeneity on biomarker testing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Y. Yatabe, JP</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Genomic heterogeneity and clonal evolution in NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Bubendorf, CH</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room W</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:50</td>
<td>How to deal with multifocal adenocarcinoma?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: J. Shrager, US; E. Felip, ES</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Surgical strategies and planning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Shrager, CA/US</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>The role of EGFR TKIs in non-metastatic multifocal adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Felip, ES</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room X</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:50</td>
<td>Immunotherapy and translational research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: M. Krebs, UK; J. Corral, ES</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:20</td>
<td>Immune-checkpoint blockade for the treatment of advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Corral, ES</td>
<td></td>
</tr>
<tr>
<td>08:20 - 08:40</td>
<td>The promises and pitfalls of liquid biopsy for the molecular portrait and monitoring of treatment response in NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Krebs, UK</td>
<td></td>
</tr>
<tr>
<td>08:40 - 08:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
## Functional evaluation early stage lung cancer

**Room A**

**Chair:** D. Grunenwald, FR

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:20</td>
<td>Cardiopulmonary function testing: What makes sense?</td>
<td>A. Brunelli, UK</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Preoperative risk models: The choice between surgery and stereotactic RT</td>
<td>E. Lim, UK</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Predicted postoperative lung function: How low can we go?</td>
<td>D. Waller, UK</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>What functional evaluation before chemoradiation?</td>
<td>J. Belderbos, NL</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Questions and Answers</td>
<td></td>
</tr>
</tbody>
</table>

## Advanced NSCLC

**Room C**

**Chair:** K. Kerr, UK; J. Vansteenkiste, BE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:15</td>
<td>97O - EGFR mutant subset analysis from ARCHER 1009: A randomized double blind phase 3 efficacy and safety study of dacomitinib versus erlotinib for the treatment of advanced non-small cell lung cancer (NSCLC)</td>
<td>L. Paz-Ares(^1), K. O'Byrne(^2), T. Mok(^3), M. Boyer(^4), P. Jänne(^5), Z. Goldberg(^6), C. Mather(^6), I. Taylor(^6), H. Zhang(^6), S. Ramalingam(^7), (^1)UK, (^2)AU, (^3)CN, (^4)NSW/AU, (^5)US, (^6)NY/US, (^7)GA/US</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>LBA3 - A phase I study of AZD9291 in patients with EGFR-TKI-resistant advanced NSCLC – updated progression free survival and duration of response data</td>
<td>P. Jänne(^1), M.-J. Ahn(^2), D.-W. Kim(^2), S.-W. Kim(^2), D. Planchard(^3), S. Ramalingam(^4), P. Frewer(^5), M. Cantarini(^5), G. Ghiorghi(^5), J. Yang(^6), (^1)US, (^2)KR, (^3)FR, (^4)GA/US, (^5)UK, (^6)TW</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Invited Discussant</td>
<td>K. O'Byrne, AU</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>98O_PR - Targeted therapy for BRAF-mutant lung cancer: Results from the European EURAF cohort study</td>
<td>O. Gautschi(^1), M. Bluthgen(^2), E. Smit(^3), J. Wolf(^4), M. Früh(^1), S. Peters(^1), M. Schuler(^4), G. Zalcman(^2), J. Milia(^2), J. Mazieres(^2), (^1)CH, (^2)FR, (^3)NL, (^4)DE</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>99O - Phase 1/2 study of AP26113 in patients (Pts) with advanced malignancies, including anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Analysis of safety and efficacy at selected phase 2 doses</td>
<td>R. Rosell(^1), S. Gettinger(^2), L. Bazhenova(^3), C. Langer(^2), R. Salgia(^4), K. Gold(^5), A. Shaw(^2), D. Dorer(^2), D. Kerstein(^2), D.R. Camidge(^6), (^1)ES, (^2)US, (^3)CA/US, (^4)IL/US, (^5)TX/US, (^6)CO/US</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Invited Discussant</td>
<td>R. Dziadziuszko, PL</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Room</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>Can adaptive design help to proceed in clinical trials in lung cancer?</td>
<td>Room B</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Carbone, US; E. Felip, ES</td>
<td></td>
</tr>
<tr>
<td>09:15 - 09:25</td>
<td>Introduction and first vote</td>
<td></td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>5 reasons pro</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Besse, FR</td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:05</td>
<td>5 reasons contra</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Buyse, BE</td>
<td></td>
</tr>
<tr>
<td>10:05 - 10:15</td>
<td>Second vote and conclusions</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Quality management in thoracic oncology</td>
<td>Room W</td>
</tr>
<tr>
<td></td>
<td>Chair: A. Rich, UK; J.-P. Sculier, BE</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Guidelines in thoracic oncology: A European point of view</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Paesmans, BE</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>National and local care for patients with thoracic malignancies across Europe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Rich, UK</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Quality of training in thoracic oncology: The HERMES programme</td>
<td></td>
</tr>
<tr>
<td></td>
<td>F. Gamarra, DE</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>The European Initiative for Quality Management in Lung Cancer Care (EIQMLCC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T. Blum, DE</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>New WHO classification: Putting it into practice</td>
<td>Room X</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Small biopsy and cytology diagnosis</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Adenocarcinoma: What are the issues?</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Tumours with squamous differentiation: What are the issues?</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Undifferentiated tumours: What are the issues?</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:30</td>
<td>Approach to sulcus superior tumours</td>
<td>Room C</td>
<td>E. Vallières, US; D. Grunenwald, FR</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>Introduction</td>
<td></td>
<td>E. Vallières, US</td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>Vertebral resection</td>
<td></td>
<td>J. Schirren, DE</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>The role of systemic therapy</td>
<td></td>
<td>E. Smit, NL</td>
</tr>
<tr>
<td>12:05 - 12:20</td>
<td>The role of radiotherapy</td>
<td></td>
<td>P. Van Houtte, BE</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Room</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Are there new targets in advanced NSCLC?</td>
<td>Room B</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Update of the French oncogenic platform</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Squamous carcinoma and its own targets</td>
<td>DE</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Lung cancer master protocols in the US</td>
<td>US</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>New targets relevant after the era of EGFR and ALK</td>
<td>ES</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:30</td>
<td>Locally-advanced NSCLC: Addressing the challenges of large-volume disease</td>
<td>Room A</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Large volume LA-NSCLC disease: Definition and outcomes</td>
<td>NL</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Is concurrent CT-RT superior in all large volume tumours?</td>
<td>BE</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Use of IMRT and proton therapy: Experimental or ready for prime-time?</td>
<td>DE</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>How to incorporate new agents and immunotherapy into the stage III treatment paradigm?</td>
<td>PL</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers / Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 13:10</td>
<td>Poster lunch</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:30</td>
<td>TUMOUR BIOLOGY AND PATHOLOGY</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:30</td>
<td>2P - EGFR mutation is not a rare issue for peripheral squamous carcinoma of lung</td>
<td>CN</td>
</tr>
<tr>
<td>12:30 - 12:30</td>
<td>3P - EGFR mutations in non-small cell lung cancer in South Africa</td>
<td>ZA</td>
</tr>
</tbody>
</table>
12:30 - 12:30 5P - Reliable EGFR mutation testing in ultrasound guided supraclavicular lymph node fine needle aspirates: A cohort study with diagnostic performance analysis
A. Awwad, S. Tiwari, V. Sovani, D. Baldwin, M. Kumaran; UK

12:30 - 12:30 6P - Screening for the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients in the Levant area, a prospective analysis

12:30 - 12:30 7P - Frequency of ALK gene rearrangement in Saudi lung cancer
F. Al Dayel, H. Al Husaini, S. Mohammed, A. Tulbah, K. Al Kuraya; SA

12:30 - 12:30 8P - PD1/PD-L1 expression in NSCLC differs according to localisation, grading and subtype
F. Brühl, A. Csanadi, C. Kayser, S. Wiesemann, J. Rawluk, M. Werner, G. Kayser; DE

12:30 - 12:30 9P - Distribution of T cells in non-small cell lung cancer tissue according to COPD and smoking status
J. Jackute, M. Zemaitis, D. Pranys, B. Sitkauskiene, S. Miliusakas, R. Sakalauskas; LT

12:30 - 12:30 10P - Allele frequency of ABO and Rh blood group and the risk of non small cell lung carcinoma
A. Kapoor, N. Kumar, A. Kalwar, S. Narayan, R. Nirban, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar, A. Sharma; IN

12:30 - 12:30 11P - The comparative estimation of estrogen receptor beta expression in primary and metastatic lung cancer
T. Bogush, E. Dudko, E. Bogush, A. Grishanina, V. Kirsanov, R. Ramanauskaita, P. Polotsky, S. Tjulandin, M. Davydov; RU

12:30 - 12:30 12P - A molecular case–control investigation of the merkel cell polyomavirus prevalence in Vietnamese non-small-cell lung-cancer
T. Ngo, VN

12:30 - 12:30 13P - Expression of IRAK-1 and EZH-2 in imprints of NSCLC and preneoplastic lesions
K. Hainis, A.-M. Athanassiadou, E. Haini, A. Tsipis, M. Gonidi, P. Athanassiadou; GR

12:30 - 12:30 14P - “Different trend” in multiple primary lung cancer and intrapulmonary metastasis
C. Shen, G. Che; CN

12:30 - 12:30 15P - Clinicopathological analysis of primary pulmonary lymphoepithelioma-like carcinoma
C. Shen, G. Che; CN

12:30 - 12:30 16P - Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing
Y. Shi, D. Tao, S. Yang, X. Han, D. Wu, N. Zhang; CN

12:30 - 12:30 17P - Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) of the lung using next-generation sequencing (NGS)
N. Chilingirova, L. Balabanski, D. Toncheva, G. Kurteva, D. Damyanov, P. Chilingirov; BG

12:30 - 12:30 18P - Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as serum marker of bone metastases from non-small cell lung cancer (NSCLC) and breast cancer. Preliminary results
F. Lumachi, A. Del Conte, F. Mazza, S. Basso, G. Chiara; IT
12:30 - 12:30 19P - Fine needle aspiration cytology of thymic epithelial neoplasms: A cytologic-histologic correlation analysis from a referral institution  
F. J. Templo, PH

12:30 - 12:30 PREVENTION, EARLY DETECTION, EPIDEMIOLOGY, TOBACCO CONTROL

12:30 - 12:30 25P - A common BIM deletion polymorphism was associated with the risk of lung cancer in a Chinese population  
X. Jing, CN

12:30 - 12:30 27P - Characteristics of lung cancer diagnosed with low dose chest CT screening  
S. Choi, C. Lee; KR

12:30 - 12:30 28P - Sex differences in presentation, management and prognosis of Moroccan patients with non small cell lung carcinoma: A retrospective analysis of 224 cases  
L. Amaadour, L. Boudahna, Z. Benbrahim, S. Arifi, N. Mellas; MA

12:30 - 12:30 29P - The risk of lung cancer among women who start smoking as teenagers  
M. Tagbarha, NG

12:30 - 12:30 30P - The beliefs, orientation, knowledge, understanding, attitudes and treatment access to lung cancer amongst rural men in Nigeria  
M. Tagbarha, NG

12:30 - 12:30 31P - Plasma CRABP2 in patients with non-small cell lung cancer  
S.-S. Han, H.-Y. Lee, S.-J. Lee, W.J. Kim, Y. Hong, E.J. Lee; KR

12:30 - 12:30 32P - Epidemiology, treatment patterns and survival outcome in patients of advanced stage inoperable lung cancer: A tertiary cancer care centre analysis  
D. Kumar, M. Pant, S. Singh; IN

12:30 - 12:30 33P - Idiopathic pulmonary fibrosis as a poor prognostic factor in lung cancer patients  
C. Son, S. Um, M.-S. Roh; KR

12:30 - 12:30 TRANSLATIONAL RESEARCH

12:30 - 12:30 41P - The comparative estimation of TUBB3 expression in non-small-cell lung carcinoma and adjacent lung tissue  
T. Boqush, I. Mamichev, E. Dudko, A. Grishanina, R. Ramanauskaite, N. Vichljantzeva, S. Tjulandin, B. Polotsky, M. Davydov; RU

12:30 - 12:30 42P - Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells  
M. Filipiska, M. Skrzypski, G. Stasioj, J. Bigda; PL

12:30 - 12:30 43P - miR31-3p expression in patients with advanced lepidic adenocarcinoma (L-ADC) treated with EGFR TKI in IFCT 0401 and 0504 trials  

12:30 - 12:30 44P - Upregulated miRNA 21 in KRAS mutated patients is related to prognosis in resectable non-small cell lung cancer
12:30 - 12:30 45P - MicroRNA expression profiling in lung cancer and normal tissue using massively parallel sequencing technique

12:30 - 12:30 46P - Antitumor efficacy of the double suicide genes in lung cancer cells
C. Shen, G. Che; CN

12:30 - 12:30 47P - Pharmacogenetics & treatment outcome in cancer patients receiving radio-chemotherapy
S. Yadav, V. Chauhan, D. Parmar; IN

12:30 - 12:30 48P - Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derived xenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
E. Stewart, S. Sakashita, T. Wang, N.-A. Pham, M. Li, G. Liu, M. Tsao; ON/CA, CA

12:30 - 12:30 49P - Synergistic effect of histone deacetylase inhibitor in combination with epidermal growth factor tyrosine kinase inhibitor in EGFR-TKI resistant non-small cell lung cancer cell lines
X. Han, N. Zhang, J. Yao, Y. Shi; CN

12:30 - 12:30 50P - Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector, an effective in vivo device for capturing CTCs

12:30 - 12:30 51P - Gef gene: A new suicide gene therapy for non-small cell lung cancer

12:30 - 12:30 52P - Multiparameter ploidy profiling: A powerful tool to investigate the genomics of diploid tumor populations
T. Lorber, S. Rau, V. Perrina, M. Barrett, C. Ruiz, L. Bubendorf; CH, AZ/US

12:30 - 12:30 IMAGING AND STAGING

12:30 - 12:30 55P - Proposed new simple criteria of clinical multiple primary lung cancers
T. Matsunaga, K. Suzuki, K. Takamochi, S. Oh; JP

12:30 - 12:30 56P - FDG PET/CT for evaluation of mediastinal lymph node staging using FDG uptake and volumetric CT histogram in non-small cell lung cancer

12:30 - 12:30 SCLC

12:30 - 12:30 57P - Inhibition of the focal adhesion kinase has anti-tumoral effect in small-cell lung cancer cell lines
12:30 - 12:30 58P - Radiation therapy (RT) in the palliative treatment of metastatic small cell lung cancer (SCLC)
Y. Ragulin, I. Ivanova, I. Gulidov, Y. Mardynsky, A. Zolotkov, D. Gogolin, L. Kursova; RU

12:30 - 12:30 EARLY STAGE NSCLC

12:30 - 12:30 66P - Prognostic classification of lung adenocarcinoma by integrated miRNA-mRNA expression profiles
S. Tam¹, M. Pintilie¹, N. Liu¹, J. McPherson², M. Tsao²; ¹ON/CA, ²CA

12:30 - 12:30 67P - mRNA expression level of lymphangiogenesis-associated genes in early-stage non-small cell lung cancer
O. Kowalczyk, M. Kozlowski, W. Laudanski, J. Kisluks, J. Niklinski; PL

12:30 - 12:30 68P - The utility of actinin-4 protein overexpression as a predictive biomarker for therapeutic effect of adjuvant chemotherapy to the resected lung adenocarcinoma
H. Shiraishi¹, Y. Fujiwara¹, T. Kakuya¹, K. Tsuta¹, S. Watanabe¹, W. Huang², T. Yamada¹, H. Asamura¹, Y. Ohe¹, K. Honda¹, ¹JP, ²TW

12:30 - 12:30 69P - The impact of genetic alteration on recurrence in patients with resected stage I non-small cell lung cancer
H.S. Chung, E.Y. Heo, S.S. Park, Y.S. Park, Y.W. Kim, D.K. Kim; KR

12:30 - 12:30 70P - Prognostic role of T-regulatory cells in completely resected early stage non-small cell lung carcinoma
F. Kose¹, H. Abali¹, A. Frndkcoglu¹, T. Canpolat¹, A. Besen¹, A. Sumbul¹, H. Mertsoylu², A. Sedef¹, O. Ozyilkın¹, ¹TR, ²TN

12:30 - 12:30 71P - Outcome after SBRT for potentially operable NSCLC patients

12:30 - 12:30 72P - Occurrence of significant tumor volume changes during stereotactic body radiation therapy for lung cancer
F. Charlier, L. Moretti, Y. Jourani, T. de Brouwer, P. Van Houtte; BE

12:30 - 12:30 73P - Outcome of early-stage lung cancer treated with stereotactic body radiotherapy (SBRT)
M. Alameddine, J. Chan, A. Pope, A. Haridass, A. Baker, S. Meara, R. Clements, A. Crabtree, H. Wong, C. Eswar; UK

12:30 - 12:30 74P - Does a higher surgical resection rate in lung cancer lead to a higher rate of post-operative multi-station N2 disease?

12:30 - 12:30 75P - Adequacy of lymph node sampling during surgical resection of lung cancer at a regional UK thoracic surgical centre 2011-2013

12:30 - 12:30 76P - Result of the 6-minute walk test is an independent prognostic factor of surgically treated non-small cell lung cancer
T. Marjanski, M. Badocha, D. Wnuk, A. Mosiewicz, W. Rzyman; PL
12:30 - 12:30  **77P - Post-operative outcomes in non-small cell lung cancer patients with mild to moderate stage chronic obstructive pulmonary disease**

12:30 - 12:30  **78P - Examination of prognostic factors in cases receiving UFT as postoperative adjuvant chemotherapy for lung cancer**
K. Nawa, R. Yoneyama, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda; JP

12:30 - 12:30  **79P - Volume changes with hypo-fractionated radiotherapy in early lung cancer: Time trends & outcomes**
R. Pathak, A. Tibdewal, S. Ghosh Laskar, S. Chaudhari, J.P. Agarwal; IN

12:30 - 12:30  **80P - Role of treatment in international differences in one-year mortality from early stage non-small cell lung cancer: A tentative answer from the International Cancer Benchmarking Partnership study**
T. Solomon¹, M. Peake¹, J. Butler¹, M. Coleman¹, W. Evans², E. Jakobsen³, M. Boyer⁴, T. Johannesen⁵, B. Rachel¹, ¹UK, ²ON/CA, ³DK, ⁴NSW/AU, ⁵NO

12:30 - 12:30  **LOCALLY ADVANCED NSCLC**

12:30 - 12:30  **84P - Trimodality therapy including radical resection for pancoast tumors: T4 is not a contraindication for radical surgery**
M. Hoda, R. Waseda, T. Klikovits, O. Foesleitner, S. Zochbauer-Mueller, K. Dieckmann, H. Prosch, R. Pirker, W. Klepetko; AT

12:30 - 12:30  **85P - Review of radical radiotherapy +/- chemotherapy for stage III NSCLC**
M. Button, R. Evans, E. Rees, C. Bullock; UK

12:30 - 12:30  **86P - Can concurrent chemo-radiation be delayed by induction chemotherapy in the curative treatment of stage III non-small cell lung carcinoma?: A pooled analysis**
C. Guilbaud¹, A. Garant², M. Almajed¹, S. Faria¹, S. Owen¹, M. Duclos¹, L. Ofiara¹, J. Gruber¹, V. Hirsh¹, N. Kopek¹, ¹QC/CA, ²CA

12:30 - 12:30  **87P - What to do for the treatment of non small cell lung cancer (NSCLC) with a single mediastinal lymph node involvement (N2a disease) in developing countries?**
F. Caushi, H. Hafizi, A. Mezini, D. Xhemalaj, I. Skenduli; AL

12:30 - 12:30  **88P - Omission of elective nodal irradiation has no impact on isolated elective nodal failure and survival outcomes in stage III non-small-cell lung cancer patients treated with definitive concurrent chemoradiotherapy**
E. Topkan, O. Guler, B. Yildirim; TR

12:30 - 12:30  **89P - Clinical factors of nodal upstaging in pathologic N1 or N2 non-small cell lung cancer**
Y. Moon, S.W. Sung, K.S. Kim, J.K. Park; KR

12:30 - 12:30  **90P - Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin in inoperable stage III non-small cell lung cancer**
H. Mertcsoglu¹, F. Kose², A. Sedef², O. Dogan², C. Parlak², A. Besen², A. Sumbul², A. Sezer², A. Fndkcoglu², S. Muallaoglu², ¹TN, ²TR
12:30 - 12:30 91P - Definitive concomitant radiochemotherapy (RCT) treatment for locally advanced (LA) non small cell lung cancer (NSCLC): Evaluation of hematological and esophageal toxicity in the Radiation Oncology Department of University of Florence experience
V. Scotti, D. Scartoni, I.F. Furfaro, G. Simontacchi, C. De Luca Cardillo, B. Agresti, C. Talamonti, L. Livi; IT

12:30 - 12:30 92P - Social deprivation and radical treatment of stage III NSCLC
M. Button, R. Evans, C. Bullock, E. Rees; UK

12:30 - 12:30 93P - The clinical characteristics of 50 patients with radiation-induced pneumonia
R. Liu, O. Zhang, X. Wang; CN

12:30 - 12:30 94P - Lung cancer in women, a different disease: Survival differences by sex
A. Ulas, S.T. Tokluoglu, M. Kös, K. Silay, S. Akinci, B. Oksuzoglu, N. Alkis; TR

12:30 - 12:30 ADVANCED NSCLC

12:30 - 12:30 111P - Ceritinib treatment of patients (Pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases: ASCEND-1 trial experience

12:30 - 12:30 112P - Efficacy and safety of imprime PGG, a novel innate immune modulator, in combination with bevacizumab (Bev), carboplatin and paclitaxel for the 1st-line treatment of stage IV NSCLC
A. Braun1, W. Engel-Riedel2, F. Schneller2, M. Wolf2, W. Schuette2, J. Lowe1, P. Mattson1, M. Gargano1, M. Patchen1, R. Huhn1; 1US, 2DE

12:30 - 12:30 113P - Anlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer: A multicentre, randomized, double-blind, placebo-controlled, phase II trial (NCT01924195)
B. Han, K. Li, Y. Zhao, B. Li, Y. Cheng, J. Zhou, Y. Lu, Y. Shi, Z. Wang, L. Jiang; CN

12:30 - 12:30 114P - A phase 1b study of anti-DLL4 (delta-like ligand 4) antibody demcizumab (DEM) with pemetrexed (PEM) and carboplatin (CARBO) in patients with 1st-line non-squamous NSCLC
J. Dupont1, M. McKeage2, D. Kotasek3, B. Markman3, M. Hidalgo4, M. Millward5, M. Jameson2, D. Harris2, R. Stagg6, B. Hughes7; 1CA/US, 2NZ, 3AU, 4ES, 5WA/AU, 6US, 7QLD/AU

12:30 - 12:30 115P - KIF5B & CCDC6 RET in lung cancer: Clinical insights and response to personalized based therapy

12:30 - 12:30 116P - Clinical characteristics and response to EGFR TKI in never smoker squamous lung cancer
S. Fe, S. Young, E.H. Tan, D. Lim, G.S. Tan, A. Jain, W. Zeng, T. Lim, A. Takano, D. Tan; SG

12:30 - 12:30 117P - German country-wide surveys from 2012 and 2014 about EGFR mutational testing algorithms adopted by medical doctors in patients with NSCLC
H. Ostermann, D. Ukena, S. Radke, A. Freitag, S. Hörnig; DE

12:30 - 12:30 118P - Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer: Phase IIIB study
B. Zaric, B. Perin, M. Cekic, M. Rancic, V. Kovcin, Z. Andric, Z. Murtezani, D. Jovanovic, M. Velinovic, M. Markovic; RS
12:30 - 12:30 119P - Reversible versus irreversible EGFR tyrosine-kinase inhibitors for non-small-cell lung cancer (NSCLC): A preclinical and pharmacokinetic comparison
B. Liederer¹, T. Friess², D. Shames¹, M. Wright¹, C. Hop¹; ¹CA/US, ²DE

12:30 - 12:30 120P - Is switch maintenance therapy mandatory for EGFR mutated patients initiated on chemotherapy?
R. Roy, IN

12:30 - 12:30 121P - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations
Y. Zhang, B. Han, B. Jin, Y. Lou, R. Li, X. Zhang, S. Hu; CN

12:30 - 12:30 122P - Icotinib as first-line treatment for elderly patients with EGFR 19 or 21 mutation in advanced NSCLC: A phase-IV, open-label, single-arm study
B. Han, C. Shi, J. Qian, R. Li; CN

12:30 - 12:30 123P - Outcomes of octogenarian (80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience from The Christie Hospital
M. Howell, J. Chiramel, N. Flaum, A. Lewis, Y. Summers, P. Taylor, A. Chittal, H. Sheikh, F. Blackhall, R. Califano; UK

12:30 - 12:30 124P - Platinum based chemotherapy for the treatment of elderly patients with metastatic non small cell lung carcinoma: A retrospective analysis of a single institution
L. Amaadour, L. Boudahna, Z. Benbrahim, S. Anfi, N. Mellas; MA

12:30 - 12:30 125P - A prospective randomized phase III study of palliative chemotherapy versus best supportive care in elderly patients with advanced non-small cell lung cancer: Survival analysis and ECOG performance status regression analysis
N. Kumar, A. Kapoor, A. Kalwar, S. Narayan, M. Singhal, A. Kumar, S. Lal, R. Nirban, M. Paramanandhan, R. Purohit; IN

12:30 - 12:30 126P - Outcomes over a decade in stage IV non-small cell lung cancer (NSCLC): The Clatterbridge Cancer Centre experience
C. Escriu, H. Wong, E. Marshall; UK

12:30 - 12:30 127P - A prospective randomized phase III study evaluating quality of life in advanced non-small cell lung cancer receiving platinum based chemotherapy combination in old versus new standard chemotherapy regimen
A. Rungta, A. Kapoor, S. Dutta; IN

12:30 - 12:30 128P - Comparison of efficacy of pemetrexed plus platinum and non-pemetrexed plus platinum as 1st line chemotherapy in EGFR wild type non-squamous NSCLC

12:30 - 12:30 129P - Effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous non-small cell lung cancer

12:30 - 12:30 130P - Maintenance pemetrexed in NSCLC - outcome analysis from a tertiary care center
A. Pandey, K. Prabhash, V. Noronha, A. Joshi; IN

12:30 - 12:30 131P - Duration and tolerance of maintenance pemetrexed (mPem) treatment for advanced non-small cell lung cancer
12:30 - 12:30 132P - Weekly carboplatin and paclitaxel in advanced non-small cell lung cancer: Good response rate but poor overall survival in a "real world" population
M. Mark¹, V. Volk², U. Mey¹, P. Brossart², R. Von Moos¹, R. Cathomas¹; ¹CH, ²DE

12:30 - 12:30 133P - An estimation of the population-based survival benefit of first-line chemotherapy for lung cancer
V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton; AU

12:30 - 12:30 134P - Effect of haematological adverse effects occurring during chemotherapy on response to treatment and progression free survival in advanced NSCLC
A. Nagy, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel; EG

12:30 - 12:30 135P - Significance of thyroid transcription factor 1 expression in patients with nonsquamous NSCLC treated with pemetrexed based chemotherapy

12:30 - 12:30 136P - TTF1 expression in advanced non-small cell lung cancer: Impact on survival outcome
S. Elsamany¹, T. Al-fayea², W. Abozeed¹, A. Alzahrani², M. Farooq², W. Darwish², A. Almadani², E. Bukhari²; ¹EG, ²SA

12:30 - 12:30 137P - Risk factors for skeletal-related events in patients with non-small cell lung cancer patients with bone metastases
A. Ulas, A. Bilici, S.T. Tokluoglu, S. Akinci, K. Silay, F. Paksoy Turkoz, A. Durnali, B. Oksuzoglu, N. Alkis; TR

12:30 - 12:30 METASTASES TO AND FROM THE LUNG

12:30 - 12:30 146P - Stereotactic ablative radiotherapy (SART) of lung lesion in oligometastatic patients: The importance of high doses delivery

12:30 - 12:30 147P - Different metastatic pattern according to the EGFR mutational status in a cohort of lung adenocarcinomas (ADCs): A single-institution report
A. Russo, T. Franchina, A. Picone, G. Ferraro, M. Picciotto, M. Zanghi, V. Franchina, V. Adamo; IT

12:30 - 12:30 148P - Incidence of brain metastases identified upon initial diagnosis in different histological types of lung cancer: A single department experience
G. Drpa, F. Popovic, I. Markelic, S. Kukulj; HR

12:30 - 12:30 149P - Presentation and patterns of care of lung cancer patients with brain metastasis at a tertiary care centre in India
A. Tibdewal, R. Pathak, S. Ghosh Laskar, K. Prabhash, G. Karimundackal, J.P. Agarwal; IN

12:30 - 12:30 150P - Usefulness of lung palpation through thoracotomy for metastasectomy in patients with non-imaged pulmonary nodules
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30 151P - Post-treatment effects of lung cancer on spinal fracture
M. Tagbarha, NG
12:30 - 12:30 152P - Transarterial chemoembolisation using drug-eluting microspheres DEM-TACE in lung carcinoma metastases to the liver in humans
B. Rybacka-Chabros, K. Pyra, T. Jargieo, M. Szczerbo Trojanowska, P. Chabros, J. Milanowski; PL

12:30 - 12:30 153P - Factors affecting survival in patients with pulmonary metastases from colorectal cancer with previously resected liver metastases who underwent lung metastasectomy
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30 154P - Surgical treatment of synchronous lung metastasis in patient with osteosarcomas and soft tissue sarcomas
E. Smolenov, Y. Ragulin, A. Starodubtcev, A. Kurilchik, V. Usachev, A. Zubarev, V. Ivanov; RU

12:30 - 12:30 MESOTHELIOMA

12:30 - 12:30 157P - Pleural malignant mesotheliomas over-express PD-L1
A. Vose1, J. Xiu2, S. Millis2, Z. Gatalica3; 1CH, 2AZ/US, 3US

12:30 - 12:30 158P - New therapeutic approach for mesothelioma
Y. Sakata, M. Takahashi, Y. Ino, T. Todo, N. Ikeda; JP

12:30 - 12:30 159P - Impact of maintenance pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: A single institution experience
T. Franchina, A. Russo, A. Picone, G. Ricciardi, F. Raiti, A. Scimone, G. Chiofalo, G. Toscano, V. Adamo; IT

12:30 - 12:30 160P - Pretreatment serum albumin level is an independent prognostic biomarker in malignant pleural mesothelioma
T. Klikovits1, P. Stockhammer1, Y. Dong1, M. Jakopovic2, L. Brcic2, B. Dome1, B. Hegedus1, M. Samarzija2, W. Klepetko1, M. Hoda1; 1AT, 2HR

12:30 - 12:30 161P - Long-term survival in adults suffered from malignant mesothelioma and pulmonary tuberculosis combined - observational study
B. Rybacka-Chabros, A. Oszywa-Chabros, J. Milanowski; PL

12:30 - 12:30 162P - Statin use and survival in malignant pleural mesothelioma (MPM)
S. Cedres, A. Navarro, A. Martinez, P. Martinez, C. Ortiz, L. Fariñas, E. Felip; ES

12:30 - 12:30 163P - Solitary fibrous tumors of the pleura: Surgical treatment, analysis of our cases from September 1999 to August 2014
F. Gradica, L. Lisha, D. Argjiri, F. Kokici, A. Cami, G. Cerga, P. Hyska, P. Kapisyzi; AL

12:30 - 12:30 MISCELLANEOUS

12:30 - 12:30 164P - Quality in lung cancer care: The Victorian Lung Cancer Registry pilot initial report

12:30 - 12:30 165P - Preoperative positron emission tomography fractal biopsy of thymic epithelial neoplasm
I. Bertolaccini, G. Felloni, M. Salgarello, A. Viti, A. Bianchi, A. Terzi; IT
12:30 - 12:30 166P - Accuracy of pleural carcinoembryonic antigen (CEA) assay in patients with benign and malignant pleural effusions requiring thoracentesis
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30 167P - Improved quality of life of patients with malignant pleural effusion who underwent video-assisted minimally invasive thoracentesis and talc pleurodesis
F. Lumachi, F. Mazza, A. Del Conte, G. Chiara, S. Basso; IT

12:30 - 12:30 168P - Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success
S. Alsayed, EG

12:30 - 12:30 169P - Incidence of pain among lung cancer patients hospitalized in Palliative Care Department of Comprehensive Cancer Center – Vratsa for the period 2009 – 2013
N. Yordanov, S. Aleksandrova, D. Yordanova; BG

12:30 - 12:30 170P - Anterior mediastinal mass case series
P. Ramanathan, P. Shivanna, S. Kumar, D. Pandey, S.V.S. Deo, N.K. Shukla; IN

F. Gradica, L. Lisha, D. Argjiri, F. Kokici, A. Cami, G. Cerga, P. Hyska, P. Kapisyzi; AL

12:30 - 12:30 172P - Post-surgical follow-up for non-small cell lung carcinoma (NSCLC): Challenging current practice
F. Iqbal, M. Haris, I. Hussain, S. Ghosh; UK

12:30 - 12:30 173P - Misdiagnosis of lung tuberculosis leads to delaying in lung cancer diagnosis and treatment: Time to use anti-tuberculosis treatment judiciously
R. Devgan, IN

12:30 - 12:30 174P - Mesenchymal tumors of the mediastinum and the role of surgery in their treatment
F. Caushi, H. Hafizi, A. Mezini, I. Skenduli, D. Xhemalaj; AL

12:30 - 12:30 175P - A novel technique for the management of recurrant malignant pericardial effusions
N. Panagiotopoulos, D. Patrini, B. Adams, D. Lawrence; UK

12:30 - 12:30 176P - Feasibility of endoscopic transumbilical anatomic lobectomy in a canine model
Y.-H. Liu, TW

12:30 - 12:30 TRIALS IN PROGRESS

12:30 - 12:30 95TiP - A phase 3, randomised, double-blind, placebo-controlled, International study of MEDI4736 in patients with locally advanced, unresectable, stage 3 NSCLC who have not progressed following platinum-based, concurrent chemoradiation therapy (PACIFIC)
B. Creelan1, N. Iannotti1, M. Salamat2, D. Jayawardene3, M. Ballard3, P. Stockman4, S. Antonio1, 1FL/US, 2KS/US, 3MD/US, 4UK

12:30 - 12:30 138TiP - Ceritinib in patients (pts) with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) metastatic to the brain and/or leptomeninges: The phase II ASCEND-7 study
12:30 - 12:30 139TiP - Phase 2, open-label, international, non-comparative study of MEDI4736 in patients with locally advanced or metastatic, PD-L1+, stage 3B–4 NSCLC who have received 2 prior systemic treatment regimens (ATLANTIC)

J. Gray1, M. Garassino2, J. Vansteenkiste3, M. Ballas4, D. Jayawardene4, P. Stockman5, J. Powderly6, N. Rizvi7; 1FL/US, 2IT, 3BE, 4MD/US, 5UK, 6NC/US, 7NY/US

12:30 - 12:30 140TiP - AURA3 design: a randomised, Phase III study of AZD9291 versus second-line chemotherapy for patients (pts) with EGFR-TKI-resistant (T790M) advanced non-small cell lung cancer

Y.-L. Wu1, V. Papadimitrakopoulou2, S. Ghiorgiu3, A. Templeton3, T. Mok1, 1CN, 2TX/US, 3UK

12:30 - 12:30 141TiP - AZD9291, a third generation EGFR inhibitor, versus gefitinib or erlotinib in treatment-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring an EGFR-TKI-sensitising mutation (EGFRm): A randomised, phase III study (FLAURA)

S. Ramalingam1, Y. Rukazenkov2, K. Thomas2, J.-C. Soria3; 1GA/US, 2UK, 3FR

12:30 - 12:30 142TiP - Randomized, double-blind, placebo-controlled trial of evofosfamide (TH-302) in combination with pemetrexed in advanced non-squamous non-small cell lung cancer

J. Goldman1, C. Belani2, S. Novello3, J. von Pawel4, T. Csoszi5, S. Orlov6, S. Kroll1, T. Pearce2; 1CA/US, 2US, 3IT, 4DE, 5HU, 6RU

12:30 - 12:30 143TiP - SPECTAlung: Screening patients with thoracic tumors for efficient clinical trial access

B. Besse1, J. Menis2, J. Adam1, R. Dziadziuszko3, B. Hasan2, L. Lacroix1, S. Peters4, D. Lacombe2, M. O’Brien5, R. Stahel2, 1FR, 2BE, 3PL, 4CH, 5UK

12:30 - 12:30 144TiP - Open-label single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R) who have failed first-line treatment with platinum-based chemotherapy

S. Thongprasert1, H. Jones2, A. Cseh3, R. Gaafar4, 1TH, 2UK, 3AT, 4EG

14:30 - 16:00 Multidisciplinary Tumour Board: How do we approach oligoprogressive disease? Room B
Chair: U. Ricardi, IT; D. Grunenwald, FR; J. Vansteenkiste, BE

14:30 - 14:55 Epidemiology, early stage NSCLC and surgery Room V
Chair: G. Rocco, IT; E. Quoix, FR; J.-P. Sculier, BE

14:30 - 15:00 Controlled EGFR mutant disease and one rapidly growing lung nodule Y.-L. Wu, CN

15:00 - 15:30 Crizotinib-controlled ALK positive disease and three brain metastases M. Guckenberger, CH

15:30 - 16:00 Cycle 28 pemetrexed maintenance therapy and one enlarging adrenal gland F. de Marinis, IT

14:30 - 15:45 Epidemiology, early stage NSCLC and surgery Room V
Chair: G. Rocco, IT; E. Quoix, FR; J.-P. Sculier, BE

14:30 - 14:30 21PD. PR - Perception of lung cancer (LC) risk: Impact of smoking status and nicotine dependence
14:30 - 14:30

D. Tataru, R. Jack, H. Møller, M. Lüchtenborg; UK

14:30 - 14:40

Invited Discussant
E. Quoix, FR

14:40 - 14:45

Discussion

14:45 - 14:45

22PD - Body mass index and lung cancer survival: Results from the ICARE study

14:45 - 14:45

24PD - Predicting Early Lung Cancer Using Big Data
Y. Ge, L. Ma, L.W. Tao, M.F. Han, L.M. Ma; CN

14:45 - 14:45

54PD - Advantages of diffusion weighted imaging of pulmonary nodules and masses: Comparison with positron emission tomography

14:45 - 14:45

65PD - Prognostic influence of mutational status in resected non-small cell lung cancer: The KRAS G12V worse value

14:45 - 15:05

Invited Discussant
J.-P. Sculier, BE

15:05 - 15:15

Discussion

15:15 - 15:15

63PD - Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: Results from propensity score analysis
S. Mokhles, N.E. Verstegen, A. Maat, O. Birim, A. Bogers, M. Mokhles, F. Lagerwaard, S. Senan, J. Takkenberg; NL

15:15 - 15:15

64PD - Effect of comorbidity on surgery and survival among lung cancer patients in England
M. Lüchtenborg, S. Riaz, R. Jack, M. Peake, M. Lind, H. Møller; UK

15:15 - 15:15

110PD - Single organ metastatic disease, a new prognostic factor for overall survival (OS) in stage IV non-small cell lung cancer (NSCLC)

15:15 - 15:35

Invited Discussant
G. Rocco, IT

15:35 - 15:45

Discussion
### Expanding the role of biomarkers

**Room A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:50</td>
<td>Biomarker testing beyond EGFR and ALK: Expanding the list of tests</td>
<td>C. Zhou, CN</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Biomarker testing on cytology samples</td>
<td>L. Bubendorf, CH</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Biomarker testing: Challenges in delivering the service</td>
<td>F. Hirsch, US</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td>NGS techniques: Ready for ‘prime time’?</td>
<td>R. Büttner, DE</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Questions and Answers</td>
<td></td>
</tr>
</tbody>
</table>

### ESMO-IASLC Best Abstracts

**Room B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:45</td>
<td>Investigating the utility of circulating-free tumour-derived DNA (ctDNA) in plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in European and Japanese patients (pts) with advanced non-small-cell lung cancer (aNSCLC): ASSESS study</td>
<td>M. Reck¹, K. Hagiwara², B. Han³, S. Tjulandin⁴, C. Grohe¹, T. Yoko², A. Morabito⁵, R. McCormack⁶, M. Ratcliffe⁶, N. Normanno⁵¹, DE, ²JP, ³CN, ⁴RU, ⁵IT, ⁶UK</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Detection of EGFR T790M mutation in urinary circulating tumor DNA from metastatic non-small-cell lung cancer patients</td>
<td>H. Husain¹, K. Kosco¹, S. Guerrero¹, T. Lu¹, C.R. Vibat², M. Erlander¹, V. Melnikova¹, J. Garcia-Puche, M. Delgado-Rodriguez, J. Navajas, A. Cueto; ES</td>
</tr>
<tr>
<td>17:15 - 17:35</td>
<td>Invited Discussant</td>
<td>E. Smit, NL</td>
</tr>
<tr>
<td>17:35 - 18:00</td>
<td>EGFR mutation testing and oncologist treatment choice in advanced NSCLC: Global trends and differences</td>
<td>J. Spicer¹, B. Tischer², M. Peters³, J. Spicer¹, DE, ²NSW/AU</td>
</tr>
</tbody>
</table>

---

04-18-2015
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Chair</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:50</td>
<td>Complex non T3 –T4 and non N2 resectable disease</td>
<td>X</td>
<td>Chair: D. Waller, UK; P. Thomas, FR</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Pathological N1 disease: Extent of resection</td>
<td></td>
<td>D. Waller, UK</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Invasion across the fissure: Extent of resection</td>
<td></td>
<td>P. Thomas, FR</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:50</td>
<td>Survivorship issues after stereotactic ablative RT for early-stage NSCLC</td>
<td>V</td>
<td>Chair: G. Rocco, IT; U. Ricardi, IT</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Predicting survival following SABR in early-stage NSCLC</td>
<td></td>
<td>U. Ricardi, IT</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Treatment of disease detected post-SABR</td>
<td></td>
<td>G. Rocco, IT</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>Screening and early detection</td>
<td>B</td>
<td>Chair: N. Horeweg, NL; G. Zalcman, FR</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td>Chemoprevention of lung cancer</td>
<td></td>
<td>A. De Censi, IT</td>
<td></td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Molecular markers for early detection</td>
<td></td>
<td>F. Bianchi, IT</td>
<td></td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Update on European lung cancer screening randomised and non-randomised studies</td>
<td></td>
<td>N. Horeweg, NL</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Update on CT lung cancer screening in Japan</td>
<td></td>
<td>R. Kakinuma, JP</td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Room</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------</td>
<td>-------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>Refining radiation therapy for SCLC</td>
<td>Room A</td>
<td>J. Belderbos, NL</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td>Radiobiology of SCLC and implications for treatment and research</td>
<td></td>
<td>R. Bütof, DE</td>
<td></td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Up-date time-dose-fractionation-and technique for PCI in SCLC</td>
<td></td>
<td>J. Belderbos, NL</td>
<td></td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Indications, efficacy and toxicity of PCI in limited and extensive disease</td>
<td></td>
<td>C. Le Pechoux, FR</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Thoracic radiation therapy for extensive disease</td>
<td></td>
<td>B. Slotman, NL</td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>ELCC Award Lecture</td>
<td>Room B</td>
<td>R. Stahel, CH</td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:50</td>
<td>Smoking epidemiology and smoking cessation techniques</td>
<td>Room A</td>
<td>E. Quoix, FR; V. Ninane, BE</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Molecular susceptibility for lung cancer and nicotine addiction</td>
<td></td>
<td>G. Zalcman, FR</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Smoking cessation in screening programmes</td>
<td></td>
<td>P. Boffetta, NY/US</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Smoking cessation in young people</td>
<td></td>
<td>A. Bühler, DE</td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:40</td>
<td>Do electronic cigarettes impact on smoking cessation?</td>
<td></td>
<td>E. Quoix, FR</td>
<td></td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Chair</td>
<td>Venue</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:50</td>
<td>The proper treatment algorithm for non-oncogene driven NSCLC</td>
<td>G. Scagliotti, IT; F. Hirsch, US</td>
<td>Room B</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>Optimal first line treatment</td>
<td>K. Syrigos, GR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Treatment of the relapsed patient</td>
<td>A.-M. Dingemans, NL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Chemotherapy for patients with brain metastases</td>
<td>M.-J. Ahn, KR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 - 12:40</td>
<td>Future direction: Pharmacogenomics or new chemotherapeutic agents?</td>
<td>G. Scagliotti, IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>Closing remarks</td>
<td>D. Grunenwald, FR; J. Vansteenkiste, BE</td>
<td>Room B</td>
<td></td>
</tr>
<tr>
<td>18:20 - 18:21</td>
<td>Test</td>
<td>S. Fontanella, CH</td>
<td>Hall 1</td>
<td></td>
</tr>
<tr>
<td>18:20 - 18:40</td>
<td>Test</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>